HomeCompareJNJ vs HRC

JNJ vs HRC: Dividend Comparison 2026

JNJ yields 2.14% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $2.23M in total portfolio value
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — JNJ vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $1,205,877.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + HRC for your $10,000?

JNJ: 50%HRC: 50%
100% HRC50/50100% JNJ
Portfolio after 10yr
$1.14M
Annual income
$714,089.76/yr
Blended yield
62.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
8
HRC buys
0
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJHRC
Forward yield2.14%11.38%
Annual dividend / share$5.20$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%40.3%
Portfolio after 10y$30.5K$2.26M
Annual income after 10y$4,749.88$1,423,429.65
Total dividends collected$15.6K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold

Year-by-year: JNJ vs HRC ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$10,594$274.49$12,296$1,595.93$1.7KHRC
2$11,294$360.69$15,730$2,573.05$4.4KHRC
3$12,133$476.91$21,147$4,316.00$9.0KHRC
4$13,156$635.42$30,235$7,608.15$17.1KHRC
5$14,432$854.61$46,615$14,263.36$32.2KHRC
6$16,056$1,162.76$78,712$28,834.27$62.7KHRC
7$18,175$1,604.53$148,063$63,841.01$129.9KHRC
8$21,009$2,252.68$315,890$157,462.80$294.9KHRC
9$24,911$3,229.73$778,498$440,495.17$753.6KHRC
10$30,458$4,749.88$2,256,422$1,423,429.65$2.23MHRC

JNJ vs HRC: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this JNJ vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.